Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Christoph Rollig, MD MSC, Hubert Serve, Andreas Hüttmann, MD, Richard Noppeney, MD, Carsten Müller-Tidow, Utz Krug, Claudia D. Baldus, MD, Christian H. Brandts, MD, Volker Kunzmann, MD PhD, Hermann Einsele, Alwin Krämer, MD, Kerstin Schäfer-Eckart, MD, Andreas Neubauer, MD, Andreas Burchert, MD, Aristoteles Giagounidis, MD, Stefan W. Krause, Andreas Mackensen, MD, Walter E. Aulitzky, MD, Regina Herbst, MD, Mathias Hänel, MD, Alexander Kiani, Norbert Frickhofen, MD, Johannes Kullmer, Ulrich Kaiser, MD, Hartmut Link, MD PhD, Thomas Geer, MD, Albrecht Reichle, MD, Christian Junghanss, MD, Roland Repp, MD, Frank Heits, MD, Heinz Albert Durk, Thomas Illmer, Martin Bornhäuser, MD, Markus Schaich, MD, Stefani Barbara Parmentier, MD, Martin Goerner, MD, Christian Thiede, MD, Malte von Bonin, MD, Johannes Schetelig, MD, Michael Kramer, M.Sc., Wolfgang E. Berdel, Gerhard Ehninger

Blood (2017) 130 (Supplement 1): 721.

https://doi.org/10.1182/blood.V130.Suppl_1.721.721

Published: 2017

Journal Articles

Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial

Julia Winkler, MD, Hannes Tittlbach, Wolf Roesler, MD, Julian Strobel, MD, Roland Zimmermann, MD, Stefanie Maas, MD, Bernd Spriewald, MD, Daniel Wolff, MD, Roland Repp, MD, Lambros Kordelas, MD, Michael Mach, PhD, Andreas Mackensen, MD, Thomas H. Winkler, PhD

Blood (2016) 128 (22): 502.

https://doi.org/10.1182/blood.V128.22.502.502

Published: 2016

Journal Articles

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Carsten Müller-Tidow, MD, Petra Tschanter, MD, Utz Krug, MD, Stefanie Goellner, PhD, Christoph Röllig, MD, Christian Thiede, MD, Anja Koschmieder, Martin Dugas, PhD, Joachim Gerss, PhD, Trude Butterfaß-Bahloul, Ruth Wagner, Stefan W. Krause, MD, Ulrich Kaiser, Volker Kunzmann, MD, Björn Steffen, MD, Richard Noppeney, MD, Wolfgang Herr, MD, Claudia D Baldus, Norbert Schmitz, MD, Katharina Götze, Albrecht Reichle, Martin Kaufmann, MD, Andreas Neubauer, MD, Kerstin Schäfer-Eckart, MD, Mathias Hänel, MD, Rudolf Peceny, MD, Haack Bea, Lilly Meredith, Norbert Frickhofen, MD, Michael G Kiehl, MD, Aristoteles A.N. Giagounidis, MD PhD, Martin Görner, Roland Repp, MD, Ralph Naumann, MD, Hartmut Link, MDPhD, Alexander Kiani, MD, Steffen Koschmieder, MD, Tim H. Brümmendorf, MD, Hubert Serve, MD, Gerhard Ehninger, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 946.

https://doi.org/10.1182/blood.V124.21.946.946

Published: 2014

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

The CD317-Targeted Immunotoxin HM1.24-ETA′ Efficiently Eliminates Malignant Plasma Cells in Vitro and in Vivo

Matthias Staudinger, Pia Glorius, Christian Kellner, Andreas Guenther, Roland Repp, Renate Burger, Martin Gramatzki, Matthias Peipp

Blood (2012) 120 (21): 1838.

https://doi.org/10.1182/blood.V120.21.1838.1838

Published: 2012

Journal Articles

The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Christian Kellner, Eugene A Zhukovsky, Monika Brüggemann, Michael Kneba, MD, PhD, André Schrauder, Martin Schrappe, Roland Repp, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2012) 120 (21): 1502.

https://doi.org/10.1182/blood.V120.21.1502.1502

Published: 2012

Journal Articles

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Christian Kellner, Tina Maurer, Daniela Hallack, Roland Repp, Jan G.J. van de Winkel, Paul W.H.I. Parren, PhD, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2011) 118 (21): 103.

https://doi.org/10.1182/blood.V118.21.103.103

Published: 2011

Journal Articles

Maturation of Monocyte-Derived Dendritic Cells Induced by Dual Targeting of Endocytosis Receptor and CD40

Matthias Staudinger, PhD, Inga Rebekka Catenhusen, Matthias Peipp, PhD, Christian Kellner, PhD, Roland Repp, MD, Martin Gramatzki, MD

Blood (2010) 116 (21): 4293.

https://doi.org/10.1182/blood.V116.21.4293.4293

Published: 2010

Journal Articles

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Christian Kellner, Daniela Hallack, Pia Glorius, Matthias Staudinger, Sahar Mohseni Nodehi, Tina Maurer, Roland Repp, Michel de Weers, Jan G.J. van De Winkel, Paul W.H.I. Parren, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2843.

https://doi.org/10.1182/blood.V116.21.2843.2843

Published: 2010

Journal Articles

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Pia Glorius, Anne Baerenwaldt, Christian Kellner, Matthias Staudinger, Paul W.H.I. Parren, Jan G. J. van De Winkel, Andreas Humpe, Thomas Valerius, Roland Repp, Falk Nimmerjahn, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2846.

https://doi.org/10.1182/blood.V116.21.2846.2846

Published: 2010

Journal Articles

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

Holly M. Horton, Matthew J. Bernett, Matthias Peipp, Erik Pong, Sher Karki, Seung Y. Chu, John O. Richards, Hsing Chen, Roland Repp, John R. Desjarlais, Eugene A. Zhukovsky

Blood (2010) 116 (16): 3004–3012.

https://doi.org/10.1182/blood-2010-01-265280

Published: 2010

Journal Articles

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Eugene A. Zhukovsky, PhD, Holly Horton, Ph.D, Matthias Peipp, PhD, Erik Pong, BS, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Seung Chu, PhD, Roland Repp, MD, John Desjarlais, PhD

Blood (2008) 112 (11): 881.

https://doi.org/10.1182/blood.V112.11.881.881

Published: 2008

Journal Articles

Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.

Blood (2008) 112 (11): 3274.

https://doi.org/10.1182/blood.V112.11.3274.3274

Published: 2008

Journal Articles

The Immunotoxin HM1.24-ETA′ Is a Potent Inducer of Apoptosis in Malignant Plasma Cells

Matthias Staudinger, Anja Muskulus, Renate Burger, Andreas Guenther, Roland Repp, Martin Gramatzki, Matthias Peipp

Blood (2008) 112 (11): 3658.

https://doi.org/10.1182/blood.V112.11.3658.3658

Published: 2008

Journal Articles

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider-Merck, Wim W. K. Bleeker, Michael Dechant, Thomas Beyer, Roland Repp, Patrick H. C. van Berkel, Tom Vink, Jan G. J. van de Winkel, Paul W. H. I. Parren, Thomas Valerius

Blood (2008) 112 (6): 2390–2399.

https://doi.org/10.1182/blood-2008-03-144600

Published: 2008

Includes: Supplemental data

Journal Articles

Efficient Lysis of Myeloma Cells by CD16 Positive Effector Cells with Recombinant Single Chain Bispecific Antibodies Targeting HM1.24.

Matthias Peipp, PhD, Claudia Ehlert, Matthias Staudinger, PhD, Joerg Bruenke, PhD, Georg Fey, PhD, Martin Gramatzki, MD, Roland Repp, MD

Blood (2007) 110 (11): 2752.

https://doi.org/10.1182/blood.V110.11.2752.2752

Published: 2007

Journal Articles

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Eugene Zhukovsky, PhD, Seung Chu, PhD, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Erik Pong, BS, Matthias Peipp, PhD, Roland Repp, MD, John Desjarlais, PhD

Blood (2007) 110 (11): 2335.

https://doi.org/10.1182/blood.V110.11.2335.2335

Published: 2007

Journal Articles

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, Hans-Peter Böck, Roland Repp, Hannes Wandt, Christiane Pott, John F. Seymour, Bernd Metzner, Annette Hänel, Tanja Lehmann, Frank Hartmann, Hermann Einsele, Wolfgang Hiddemann

Blood (2006) 108 (13): 4003–4008.

https://doi.org/10.1182/blood-2006-04-016725

Published: 2006

Includes: Supplemental data

Journal Articles

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Martin H. Dreyling, MD, Roswitha Forstpointner, MD, Hans-Peter Boeck, MD, Roland Repp, MD, Hannes Wandt, MD, Christiane Pott, MD, John Francis Seymour, MD, Bernd Metzner, MD, Annette Haenel, MD, Tanja Lehmann, MD, Frank Hartmann, MD, Hermann Einsele, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 2769.

https://doi.org/10.1182/blood.V108.11.2769.2769

Published: 2006

Journal Articles

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Juergen Rech, MD, Roland Repp, MD, Dorit Rech, MD, Bernhard Stockmeyer, MD, Michael Dechant, MD, Gerald Niedobitek, MD, Tilman Pearce, MD, Georg Weiner, MD, Martin Gramatzki, MD, Thomas Valerius, MD.

Blood (2005) 106 (11): 4775.

https://doi.org/10.1182/blood.V106.11.4775.4775

Published: 2005

NARROW

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

The CD317-Targeted Immunotoxin HM1.24-ETA′ Efficiently Eliminates Malignant Plasma Cells in Vitro and in Vivo

The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Maturation of Monocyte-Derived Dendritic Cells Induced by Dual Targeting of Endocytosis Receptor and CD40

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.

The Immunotoxin HM1.24-ETA′ Is a Potent Inducer of Apoptosis in Malignant Plasma Cells

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Efficient Lysis of Myeloma Cells by CD16 Positive Effector Cells with Recombinant Single Chain Bispecific Antibodies Targeting HM1.24.

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only